RDY
· Pharmaceuticals
Dr. Reddy's Laboratories
$13.52
+0.07 (+0.52%)
Open$13.49
Previous Close$13.45
Day High$13.55
Day Low$13.35
52W High$1,379.70
52W Low$1,020.00
Volume—
Avg Volume2.17M
Market Cap1.01T
P/E Ratio18.16
EPS$66.81
SectorPharmaceuticals
Analyst Ratings
Hold
45 analysts
Key Financials
| FY 2026 | FY 2025 | |
|---|---|---|
| Revenue | 29.49T | 25.68T |
| Net Income | 5.11T | 4.00T |
| Profit Margin | 17.3% | 16.5% |
| EBITDA | 8.03T | 6.64T |
| Free Cash Flow | — | — |
| Rev Growth | +14.9% | +14.9% |
| Debt/Equity | 0.14 | 0.14 |
Dividend
Dividend Yield0.66%
Annual Dividend$8.00
Payout Ratio11.8%
Frequencyquarterly
Ex-Dividend—
Pay Date—
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,006.45 | -1.46% | 37.5 | 946.93B |
| JNJ | Johnson & Johnson | $230.00 | +0.47% | 26.1 | 549.56B |
| MRK | Merck & Co. Inc. | $114.24 | +1.49% | 31.2 | 278.45B |
| PFE | Pfizer Inc. | $25.66 | +1.30% | 19.3 | 144.48B |
| BMY | Bristol-Myers Squibb Co | $58.31 | +1.74% | 19.2 | 114.93B |
| ZTS | Zoetis Inc | $79.48 | +0.71% | 12.0 | 31.64B |
RDY Frequently Asked Questions
How much does RDY stock cost right now?
RDY is currently trading at $13.52, up 0.52% in today's session. Over the past 52 weeks, the stock has traded between a low of $1,020.00 and a high of $1,379.70. The current price represents 0% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
What is the analyst consensus for RDY?
Among 45 analysts covering RDY, the consensus rating is Hold — 23 rate it a buy, 11 hold, and 11 sell. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
Does Dr. Reddy's Laboratories make money?
Dr. Reddy's Laboratories generated $29.49T in revenue during fiscal year 2026, with $5.11T reaching the bottom line as net income. The net profit margin of 17.3% is solid for its sector.
Is RDY stock expensive based on earnings?
RDY trades at a P/E ratio of 18.16 on trailing earnings of $66.81 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Pharmaceuticals sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.